Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal remifentanil for hemodynamic changes induced by electroconvulsive therapy
IRCT20200825048515N20Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of remifentanil in conditions requiring electroconvulsive therapy, sponsored by Isfahan University of Medical Sciences. Started Jan 2021; status: completed.
02
Drugs
remifentanil
03
Conditions
conditions requiring electroconvulsive therapy
Beyond the preview
Go deeper on IRCT20200825048515N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N20.